Mr. Giles brings to NOBLE Capital Markets more than 30 years of investment banking and capital markets experience. Most recently Mr. Giles was head of the technology group at Stifel Nicolaus and prior to that spent 16 years at A.G. Edwards as head of its emerging growth group that included both Edwards' technology and healthcare practices. During his career he has executed over 100 public financings raising over $4 billion for his clients, including IPOs for companies such as VMWare, COMPAQ, Cardica and ExecuStay. He also has overseen numerous M&A transactions on the buy side as well as the sell side. Mr. Giles received his AB from Harvard College and his MBA from the Harvard Business School. Mr. Giles holds various FINRA licenses and works out of the company's Boston Office.

Mr. Cooleen has dedicated his Twenty year career to serving as a trusted advisor in the brokerage and investment banking industry. He has extensive experience in growing new business as well as building existing investment banking, sales, and capital markets relationships. Deal experience gained while working on over 100 transactions including Follow-on Equity Offerings, Registered Direct Offerings, Shelf Takedowns, Initial Public Offerings, Confidentially Marketed Public Offerings, Private Investment in Public Equity, Private Placements, and Convertible Debt.

Dr Ordoñez joined NOBLE Capital Markets in 2016. He has sixteen years of experience in various segments of the healthcare capital markets. Recently, he was President and co-founder of Ciclofilin Pharmaceuticals, a San Diego based-biotechnology company, which was sold to ContraVir Pharmaceuticals. During his career, he has worked on various roles in Buy-side and Sell-Side Institutions, including Difference Capital Financial Inc., and GMP Securities Inc. in Canada. Dr Ordoñez has advised and helped raise funds for North American companies in drug development, medical device, specialty pharma and healthcare services areas. He is a Medical Doctor and obtained a Ph.D in Experimental Medicine and Biochemistry from McGill University in Montreal, Canada. He also completed post-doctoral training at the Karolinska Institute/Hospital in Stockholm, Sweden.

Christopher Ensley is a Managing Director of technology, media & telecom (TMT) investment banking at NOBLE Capital Markets where he focuses on capital raising, mergers and acquisition advisory and valuation opinions for clients. During his tenure on Wall Street, Mr. Ensley has participated in over $16B in transactions. Prior to NOBLE, Mr. Ensley was a TMT investment banker at Coady Diemar Partners, a boutique investment bank in NYC. Prior to Coady Diemar, Mr. Ensley was a Managing Director in the equity research department at Bear Stearns. While at Bear Stearns, Mr. Ensley was a member of the #1 rated broadcast equity research team for six straight years (2002-2007). Mr. Ensley was a Vice President of equity research covering the broadcast sector at Lazard. He began his Wall Street career as an equity research analyst at Salomon Brothers where he covered the tower industry in addition to the broadcasting industry. He received an MBA from Vanderbilt University and a BA from the College of William & Mary.

Nathan Cali has more than 13 years of combined healthcare, biotechnology and pharmaceutical experience. Mr. Cali's was previously a sell-side analyst for 9 years with expertise and publications cover many areas of biotechnology, specialty pharmaceuticals (branded and generics), medical devices, and regenerative medicine. He has been quoted in most business journals including Reuters, BioMed Reports and the Washington Business Journal. Mr Cali is the co-founder of Variant Pharmaceuticals an early stage biotechnology company advancing orphan drugs for the treatment of renal diseases. Mr. Cali started his career in healthcare at Andrx Corporation, a biotechnology and specialty pharmaceuticals company known for its expertise in the development of controlled-release drugs. Mr. Cali was a corporate manager dealing in finance, state taxation, corporate governance, patents, drug distribution and business development for the biotechnology firm. Andrx was purchased by Watson Pharmaceuticals in 2006 for $2.0 billion in cash. Prior to joining NOBLE, Mr. Cali gained investment experience as a portfolio account analyst/manager at Franklin Templeton Investments. Mr. Cali holds a B.S. in Finance from The Florida State University and an M.B.A. in Finance from Nova Southeastern University. Nathan also currently holds series 7, 79, 86, and 87 FINRA designations.

Francisco Penafiel joined NOBLE Capital Markets in 2002 after earning his Master of Science in Economics, with concentrations in Finance and International Economics from Florida Atlantic University. He obtained his undergraduate degree from Escuela Superior Politecnica in Ecuador, where he double-majored in Statistics and Computing Science. Prior to joining the investment banking department at Noble in 2011, Francisco was part of NOBLE's research department, working as a supervisory analyst and equity research analyst covering the enterprise/infrastructure software and business services industries. Other responsibilities included portfolio managing, computer modeling analysis and statistical review. He is also a member of the Company's Investment Policy Committee. Francisco holds various FINRA licenses and is a candidate in the CFA program.

Mr. Arvelo has more than 18 years of corporate finance and capital markets experience, with a special focus on M&A, restructuring and capital raising transactions. Mr. Arvelo has successfully completed equity placements, MBO’s, restructurings and M&A assignments in USA, Latin America and Africa. Prior to joining NOBLE, Mr. Arvelo worked as Director at Enkeros Investments and Activa Capital Markets, and has been Director (BOD), Financial Advisor and interim officer for various companies, with main focus in the QSR, financial institutions and energy sectors. After finishing his Masters in Finance, Mr. Arvelo joined the corporate finance and recoveries division at PricewaterhouseCoopers (PwC), and was responsible for M&A transactions, Corporate Valuation Consulting Services, Project Finance, Privatizations and Dispute Analysis & Investigations. Mr. Arvelo graduated in Economics from Universidad Catolica Andres Bello (B.A. 1993), holds a Masters in Finance from IESA (M.A. 1997) and also graduated Magna Cum Laude from the MBA program at Babson College, with a majors Entrepreneurship and Strategy (M.B.A. 2004).

Mark Suarez joined Noble Capital Markets as Managing Director leading the marine shipping & surface transportation investment banking practice. For over 12 years, Mark has held senior positions in investment banking and equity research. Most recently, he was a Senior Advisor for McQuilling Holdings, the investment banking arm of McQuilling Partners, focusing on the maritime space. Prior to that, between 2011 and 2015, Mark was Director of Research at Euro Pacific Capital, covering the global transportation & logistics sector. Prior to joining Euro Pacific Capital, Mark was a research analyst at Wolfe Research, covering the railroad and intermodal industries. Mark started his career at CIBC, followed by National Bank Financial (NBF), covering the surface and marine transportation space. He has been frequently quoted on industry publications like Tradewinds, JOC, Globe and Mail and TheStreet. In 2015, Thomson Reuters StarMine Analyst Awards Program named him as the number one ranked sell-side Marine Shipping Analyst in terms of earnings estimation, and number two ranked in terms of stock picking. Mark holds a Masters degree in Economics from the University of Toronto and a Bachelor of Commerce degree in Economics & Finance from McGill University. Mark is also a CFA charterholder and holds FINRA Series 7, 63, 79, 86, 87 and 24 registrations.

Mr. Joseph Hain, also known as Joey, serves as Director of Investment Banking at Noble Capital Markets. Mr. Hain served as Managing Director, Head Trader, and Portfolio Manager at the Lawrence Fund LP, where he oversaw and directed the entire trading and class action lawsuit operation. Mr. Hain is the Co-Founder and Limited Partner at Intrinsic Value Capital LP. Previously, he served as a Portfolio Manager of Robotti & Company, Incorporated, where he managed portfolios of HNW individuals and family businesses as well as served as Portfolio Manager of the Glaubman Rosenberg & Robotti Fund LP. a fundamental value focused hedge fund. Mr. Hain began investment banking in 2008 and served as Senior Vice President at WestPark Capital, Tejas Securities, Wynston Hill Capital Management, and Paulson Investment Company. Mr. Hain was also Senior Vice President at Stern Aegis Ventures an affiliate of Aegis Capital Corp. and worked with both public and private companies as well as institutional, retail and HNW clients globally. Mr. Hain is a recipient of 40 under 40 for M&A and Dealmaking from M & A Advisor, Mr. Hain is on the Advisory Board of the Naomi Berrie Center for Diabetes at Columbia University. Mr. Hain holds the following security designations: Series 7, 63, 65, and 79 FINRA Licenses. Mr. Hain received a Bachelor of Science from the State University of New York at Albany with a core concentration in Biology, Chemistry, and Physics

Dr. Victor Hartmann was formerly the head of Corporate and Strategic Development at Vertex Pharmaceuticals, head of the Business Development and Licensing and head of Global Project Management at Novartis Pharma AG, head of Clinical Research and Development at Sandoz Pharmaceutical Corporation and head of Medical Affairs at Boehringer Ingelheim. Dr. Hartmann is currently a consultant to biotechnology and pharmaceutical companies advising them on business development transactions, strategic planning and process reengineering relevant to establishing alliances.

Mr. Musing is the former Global Head of Biotechnology Licensing and Business Development and has been responsible for global Drug Licensing at Johnson & Johnson. In that position he negotiated and signed several multi-million dollar deals with medium and large pharmaceutical and biotechnology companies on a worldwide basis. He has more than 36 years' experience in the biotechnology and pharmaceutical industry and has been President and Managing Director of Johnson & Johnson Companies in the US and Europe, President of Ares Serono in the US and Executive Vice President for Ares Serono companies in North and Latin America. Mr. Musing has been on the Board of Johnson & Johnson Companies in Germany, France, Italy and the UK, and has been a Member of the Management Board of Ortho Biotech, (a J&J biotechnology company) in the US and Europe. He is currently Executive Chairman of Pelican Therapeutics and is a member of the Board of several companies including Delphi Digital and TherapeuticsMD.

Michael Lerner, Chair of Lowenstein Sandler's Life Sciences Group, has been advising pharmaceutical, life sciences and healthcare companies on key strategic matters for over 30 years. Previously, he served as VP and General Counsel at Reliant Pharmaceuticals, Inc., helping it grow into one of the nation's largest privately held pharmaceutical companies before it was acquired by GSK in 2007. As part of the senior management team, Mr. Lerner led product acquisitions and dispositions totaling in excess of $650 million, and raised more than $660 million in equity and debt. Mr. Lerner subsequently served as SVP and General Counsel of EKR Therapeutics, a specialty pharmaceutical company. Earlier in his career, Mr. Lerner was at the law firm of Gibbons PC, where he was the partner in charge of the pharmaceutical and life sciences practice. Mr. Lerner currently serves on the Board of Directors of the Blanche and Irwin Lerner Center for the Study of Pharmaceutical Management Issues, which is part of Rutgers Graduate School of Business.

Dr. Sancilio has over 40 years of experience in the pharmaceutical research, development, manufacturing and distribution industries. Prior to founding SCI, Dr. Sancilio founded three successful pharmaceutical companies, including aaiPharma Inc., a premiere contract research organization. Dr. Sancilio is an experienced pharmaceutical executive, development scientist and accomplished entrepreneur. He has published over 20 articles in peer reviewed scientific journals, holds 14 domestic and international patents and has presented in conferences around the world. Over the course of his career, he has contributed to the development of over 1,000 drugs marketed in the United States, Europe and Asia.

Since 2009, Dr. Eric J. Ende has served as President of Ende BioMedical Consulting Group, which is focused on helping life sciences companies raise capital, identify licensing partners, and optimize corporate structure as well as analyzing both private and public investment opportunities for clients within the life sciences industry. In addition, Dr. Ende served with Icahn Enterprises in their Board appointment at Forest Labs, Genzyme, Biogen IDEC, and Amylin. Dr. Ende was a Director on Genzyme’s Board from 2010 – 2011 until it was acquired by Sanofi-Aventis in 2011 for $20 B. During his tenure on Genzyme’s Board, he was a member of the Audit and Risk Management Committees. Dr. Ende is currently serving on the Technology Transfer Committee of Mount Sinai Innovation Partners and has served as the Chairman of the Unsecured Creditor’s Committee overseeing the Egenix Bankruptcy. From 2002 through 2008, Dr. Ende was the senior biotechnology analyst at Merrill Lynch. From 2000 – 2002, Dr. Ende was the senior biotechnology analyst at Banc of America Securities. And, from 1997 – 2000, he was a biotechnology analyst at Lehman Brothers. During Dr. Ende’s career as a biotechnology analyst, he was named to Institutional Investor’s All-America Equity Research Team six times as well as to The Greenwich Survey list of top analysts. He was also named Top Stock Picker by The Street.com and Best Earnings Estimator by Forbes.com. Dr. Ende received an MBA in Finance & Accounting from NYU – Stern Business School in 1997, an MD from Mount Sinai School of Medicine in 1994, and a BS in Biology and Psychology from Emory University in 1990.

Camillo Ricordi, M.D. is the Stacy Joy Goodman Professor of Surgery, Distinguished Professor of Medicine, Professor of Biomedical Engineering, and Microbiology and Immunology at the University of Miami (UM), Florida, where he serves as Director of the Diabetes Research Institute (DRI; www.diabetesresearch.org) and the Cell Transplant Program. Dr. Ricordi also served as Responsible Head of the Human Cell Processing Facility (1993-2014), an NIH funded cGMP (current Good Manufacturing Practices) facility that has been providing Human Cell Products for research and clinical applications at UM, in Florida and worldwide since 1993. Dr. Ricordi has also served as Co-Director of the Executive Office of Research Leadership (2001-2003) as Senior Associate Dean for Research (2003-2006) and chaired the Dean’s Research Cabinet (2006-2012) at the UM Miller School of Medicine.

In 2015 Dr. Ricordi led the UM – UHealth – JMH team that performed the first successful transplant of a bioengineered endocrine pancreas implanted within a 3D bioactive resorbable scaffold in the abdominal cavity of a recipient with a severe form of Type 1 Diabetes (BioHUB Project). The patient has been able to discontinue insulin treatment since the first month post-transplant with excellent metabolic control. This unprecedented success resulted in renewed enthusiasm for the possibility to engineer this transplant site with additional strategies to avoid the requirements for recipient immunosuppression, and has resulted in additional key collaborative efforts, from Harvard to Stanford and with other leading international centers. The same year Dr. Ricordi launched the DRI Translational Fast Track Program to Reverse Autoimmunity and Induce Immune Tolerance, which he co-leads with Dr. Jay Skyler, in collaboration with several key UM investigators, from the SCCC, the DRI, the Departments of Medicine, Surgery, Biomedical Engineering, Microbiology and Immunology, Molecular and Cellular Pharmacology and Epidemiology.

Dr. Ricordi was president of the Cell Transplant Society (1992-94), co-founder and chairman of the National Diabetes Research Coalition (Chairman 1997), co-founder and president (1999-2001) of the International Association for Pancreas and Islet Transplantation (IPITA), and a member of the council of The Transplantation Society (2002-2008). He also served on the council of the American Society of Transplant Surgeons (2000-2002), on the National Institutes of Health (NIH-NIAID) Expert Panel on clinical approaches for tolerance induction, on the FDA Biologic Response Modifiers Advisory Committee, on the NIH/NCRR Islet Cell Resources (ICRs) Executive Committee, on the NIH-NIDDK Strategic Planning Committee and on the NIH-NIAID Expert Panel on Transplantation Research. He is currently serving as Chairperson of the Clinical Islet Transplant Consortium (NIDDK-NIAID). He has also been serving on several NIH study sections, including Surgery, Anesthesia and Trauma, the General Clinical Research Centers, Small Business Innovative Research, the Immune Tolerance Network, in addition to serving as a reviewer for several international funding agencies.

Dr. Ricordi has received numerous honors and awards, including the 2001 Nessim Habif World Prize in Surgery (University of Geneva) for developing a technology that significantly contributed to the advancement of a surgical field